美国 · 平台与数据 · MarketBeat

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

来源：MarketBeat · 美国 1 小时前

X4 Pharmaceuticals (NASDAQ:XFOR) said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of…

在 MarketBeat 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

推荐阅读

Amerisafe (AMSF) Q3 2026 Earnings Call Transcript

Microsoft to raise up to $25 billion in bond market as investors get pickier about AI debt binge

US proposes Venezuela elections for 2027, opposition leader Machado says

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

NOW Stock On Track To Post Worst Single-Day Performance In Over 14 Years — Analysts See AI Upside Despite Slowing Growth

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

分享

推荐阅读

Amerisafe (AMSF) Q3 2026 Earnings Call Transcript

Microsoft to raise up to $25 billion in bond market as investors get pickier about AI debt binge

US proposes Venezuela elections for 2027, opposition leader Machado says

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

NOW Stock On Track To Post Worst Single-Day Performance In Over 14 Years — Analysts See AI Upside Despite Slowing Growth